RESEARCH TRIANGLE PARK, N.C., April 25, 2011 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the promotion of Douglas Krafte, Ph.D. to the newly created position of Chief Scientific Officer. In this position, Dr. Krafte will have overall scientific leadership responsibilities for the research and discovery of new targets and new chemical leads, and for each of Icagen’s research projects. In so doing, Dr. Krafte will continue to work closely with Mark Suto, Ph.D., VP of Chemistry and Pharmaceutical Sciences, and Greg Rigdon, Ph.D., VP of New Product Development and continue to report to Kay Wagoner, Ph.D., President and CEO.
